HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+5.41%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$141M
AUM Growth
+$141M
(+4.8%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
1.6%
Top 10 Holdings %
Top 10 Hldgs %
55.72%
Holding
161
New
36
Increased
33
Reduced
7
Closed
45
Top Buys
Top Sells
| 1 |
IPHI
INPHI CORPORATION
IPHI
|
$3.84M |
| 2 |
RP
RealPage, Inc.
RP
|
$3.37M |
| 3 |
iShares MSCI India ETF
INDA
|
$2.29M |
| 4 |
Genworth Financial
GNW
|
$1.92M |
| 5 |
Alibaba
BABA
|
$1.83M |
Sector Composition
| 1 | Technology | 32.85% |
| 2 | Healthcare | 32.22% |
| 3 | Financials | 6.7% |
| 4 | Communication Services | 6.68% |
| 5 | Consumer Discretionary | 4.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $796K | 0.56% |
4,926
+660
| +15% | +$107K |
|
52
Revolution Medicines
RVMD
$7.43B
| $795K | 0.56% |
25,038
+8,046
| +47% | +$255K |
|
53
Neurocrine Biosciences
NBIX
$13.5B
| $792K | 0.56% |
+8,140
| New | +$792K |
|
54
Travere Therapeutics
TVTX
$1.75B
| $781K | 0.55% |
53,498
+28,876
| +117% | +$422K |
|
55
Nurix Therapeutics
NRIX
$723M
| $779K | 0.55% |
29,380
+10,158
| +53% | +$269K |
|
|
KNTE
56
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $777K | 0.55% |
+33,391
| New | +$777K |
|
|
XLRN
57
DELISTED
Acceleron Pharma Inc.
XLRN
| $775K | 0.55% |
+6,177
| New | +$775K |
|
|
BPMC
58
DELISTED
Blueprint Medicines
BPMC
| $774K | 0.55% |
+8,805
| New | +$774K |
|
|
ONC
59
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $766K | 0.54% |
2,231
| – | – |
|
60
Xenon Pharmaceuticals
XENE
$2.99B
| $763K | 0.54% |
+40,959
| New | +$763K |
|
|
ISEE
61
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $751K | 0.53% |
118,965
-22,090
| -16% | -$139K |
|
|
FMTX
62
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $714K | 0.51% |
28,685
+8,055
| +39% | +$200K |
|
63
Aclaris Therapeutics
ACRS
$223M
| $697K | 0.49% |
+39,675
| New | +$697K |
|
64
ESSA Pharma
EPIX
$11.2M
| $686K | 0.49% |
+24,026
| New | +$686K |
|
65
MacroGenics
MGNX
$121M
| $674K | 0.48% |
25,104
-13,118
| -34% | -$352K |
|
66
Intellia Therapeutics
NTLA
$1.26B
| $597K | 0.42% |
3,685
| – | – |
|
67
Yum China
YUMC
$16.3B
| $588K | 0.42% |
8,878
-8,221
| -48% | -$544K |
|
68
Edgewise Therapeutics
EWTX
$1.54B
| $586K | 0.42% |
+27,467
| New | +$586K |
|
69
Curis
CRIS
$21.5M
| $467K | 0.33% |
57,908
-15,835
| -21% | -$128K |
|
70
Entravision Communication
EVC
$225M
| $269K | 0.19% |
40,325
+10,379
| +35% | +$69.2K |
|
71
BioCryst Pharmaceuticals
BCRX
$1.74B
| $242K | 0.17% |
15,316
| – | – |
|
72
IDT Corp
IDT
$1.64B
| $242K | 0.17% |
+6,549
| New | +$242K |
|
73
TrueCar
TRUE
$183M
| $234K | 0.17% |
41,284
+18,884
| +84% | +$107K |
|
74
QuinStreet
QNST
$875M
| $229K | 0.16% |
+12,301
| New | +$229K |
|
75
Cassava Sciences
SAVA
$107M
| $212K | 0.15% |
+2,488
| New | +$212K |
|